DE69414723T2 - Lyophilisierte stammzellenfaktor formulierungen - Google Patents

Lyophilisierte stammzellenfaktor formulierungen

Info

Publication number
DE69414723T2
DE69414723T2 DE69414723T DE69414723T DE69414723T2 DE 69414723 T2 DE69414723 T2 DE 69414723T2 DE 69414723 T DE69414723 T DE 69414723T DE 69414723 T DE69414723 T DE 69414723T DE 69414723 T2 DE69414723 T2 DE 69414723T2
Authority
DE
Germany
Prior art keywords
stem cell
cell factor
lyophilized
factor formulations
lyophilized stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69414723T
Other languages
English (en)
Other versions
DE69414723D1 (de
Inventor
Susan Hershenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of DE69414723D1 publication Critical patent/DE69414723D1/de
Application granted granted Critical
Publication of DE69414723T2 publication Critical patent/DE69414723T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
DE69414723T 1993-12-22 1994-12-21 Lyophilisierte stammzellenfaktor formulierungen Expired - Lifetime DE69414723T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/172,507 US6288030B1 (en) 1993-12-22 1993-12-22 Stem cell factor formulations and methods
PCT/US1994/014739 WO1995017206A1 (en) 1993-12-22 1994-12-21 Lyophilized stem cell factor formulations

Publications (2)

Publication Number Publication Date
DE69414723D1 DE69414723D1 (de) 1998-12-24
DE69414723T2 true DE69414723T2 (de) 1999-07-22

Family

ID=22627993

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69414723T Expired - Lifetime DE69414723T2 (de) 1993-12-22 1994-12-21 Lyophilisierte stammzellenfaktor formulierungen

Country Status (14)

Country Link
US (4) US6288030B1 (de)
EP (1) EP0732935B1 (de)
CN (1) CN1105575C (de)
AT (1) ATE173402T1 (de)
AU (1) AU696860B2 (de)
CA (1) CA2182970C (de)
DE (1) DE69414723T2 (de)
DK (1) DK0732935T3 (de)
ES (1) ES2123951T3 (de)
HK (1) HK1008815A1 (de)
IL (1) IL112088A (de)
NZ (1) NZ278252A (de)
WO (1) WO1995017206A1 (de)
ZA (1) ZA9410189B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9515839D0 (en) * 1995-08-02 1995-10-04 Q One Biotech Ltd Feline stem cell factor
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6500418B1 (en) * 1999-02-12 2002-12-31 The Washington University Stimulating neutrophil function to treat inflammatory bowel disease
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6472208B1 (en) * 1999-12-13 2002-10-29 Héma-Québec Method of producing human IFN-α using sendai virus-infected hematopoietic stem cells
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
JP4294316B2 (ja) * 2000-12-06 2009-07-08 ハリリ，ロバート，ジェイ． 胎盤幹細胞の回収方法
EP2336299A1 (de) 2001-02-14 2011-06-22 Anthrogenesis Corporation Post-partum Säugetier-Plazenta, deren Verwendung und daraus gewonnene Stammzellen
US7700090B2 (en) 2002-02-13 2010-04-20 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP3963786B2 (ja) * 2002-06-11 2007-08-22 富士通株式会社 情報処理装置
KR20050086780A (ko) 2002-11-26 2005-08-30 안트로제네시스 코포레이션 세포요법제, 세포요법제 단위 및 이를 이용한 치료방법
KR20050105467A (ko) * 2003-02-13 2005-11-04 안트로제네시스 코포레이션 질병, 장애 또는 증상을 보유하는 개체의 치료에 있어서제대혈의 용도
GB0321337D0 (en) * 2003-09-11 2003-10-15 Massone Mobile Advertising Sys Method and system for distributing advertisements
CN101966183A (zh) * 2003-12-02 2011-02-09 细胞基因公司 用于治疗和控制血红蛋白病和贫血病的方法和组合物
CA2552241C (en) 2003-12-30 2013-10-01 Durect Corporation Co-polymeric devices for controlled release of active agents
CA2610839C (en) 2005-06-14 2019-06-25 Amgen Inc. Self-buffering protein formulations
AU2006275475A1 (en) * 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
SI1957633T1 (sl) 2005-10-13 2014-04-30 Anthrogenesis Corporation Imunomodulacija z uporabo matičnih celic iz placente
KR20180105266A (ko) 2005-12-29 2018-09-27 안트로제네시스 코포레이션 태반 줄기 세포 집단
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
EP1854478A1 (de) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Formulierung eines Nikotine-Träger Impfstoffs
EP3483263A1 (de) 2006-10-23 2019-05-15 Celularity, Inc. Verfahren und zusammensetzungen zur behandlung von knochendefekten mit plazentazellenpopulationen
PT2120977E (pt) 2007-02-12 2013-09-16 Anthrogenesis Corp Tratamento de doenças inflamatórias utilizando células estaminais da placenta
US20100172830A1 (en) * 2007-03-29 2010-07-08 Cellx Inc. Extraembryonic Tissue cells and method of use thereof
TWM322542U (en) * 2007-05-23 2007-11-21 Universal Scient Ind Co Ltd Testing machine
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
KR20200043517A (ko) * 2007-09-26 2020-04-27 안트로제네시스 코포레이션 인간 태반 관류액으로부터의 혈관형성 세포
KR20150088336A (ko) 2007-09-28 2015-07-31 안트로제네시스 코포레이션 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법
NO2217329T3 (de) * 2007-11-07 2018-06-09
KR20180049231A (ko) * 2008-08-20 2018-05-10 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법
KR20200143506A (ko) * 2008-08-20 2020-12-23 안트로제네시스 코포레이션 단리된 태반 세포를 사용한 뇌졸중 치료
MX339068B (es) * 2008-08-22 2016-05-10 Anthrogenesis Corp Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias.
BRPI0922184A2 (pt) 2008-11-19 2020-08-18 Anthrogenesis Corporation célula isolada, população isolada de células, matriz ou estrutura sintética permanente ou decelularizada degradável, e , método para tratar um indivíduo
WO2010060031A1 (en) * 2008-11-21 2010-05-27 Anthrogenesis Corporation Treatment of diseases, disorders or conditions of the lung using placental cells
US8586360B2 (en) 2009-07-02 2013-11-19 Anthrogenesis Corporation Method of producing erythrocytes without feeder cells
DK3284818T3 (da) * 2010-01-26 2022-06-20 Celularity Inc Behandling af knoglerelateret kræft ved hjælp af placenta stamceller
TWI756797B (zh) 2010-04-07 2022-03-01 美商瑟魯勒瑞堤股份有限公司 利用胎盤幹細胞之血管新生
CN102933221A (zh) 2010-04-08 2013-02-13 人类起源公司 使用胎盘干细胞治疗结节病
KR20220053695A (ko) 2010-07-13 2022-04-29 셀룰래리티 인코포레이티드 천연 킬러 세포의 생성 방법
CN103403019B (zh) 2010-09-28 2016-10-12 埃格里昂制药股份有限公司 具有增强的作用持续时间的工程化多肽
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
DK2714059T3 (en) 2011-06-01 2019-01-21 Celularity Inc TREATMENT OF PAIN WHEN USING PLACENT STAM CELLS
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
WO2014123879A1 (en) 2013-02-05 2014-08-14 Anthrogenesis Corporation Natural killer cells from placenta
MA42613A (fr) 2015-08-13 2018-06-20 Amgen Inc Filtration en profondeur chargée de protéines de liaison à un antigène

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4165370A (en) 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
JPS5534001A (en) * 1978-08-28 1980-03-10 Noda Sangyo Kagaku Kenkyusho Stabilization of sarcosine oxidase
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3176491D1 (en) 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
JPS5874617A (ja) 1981-10-28 1983-05-06 Green Cross Corp:The 人由来血液凝固第７因子含有水溶液の加熱処理方法
JPS58134991A (ja) * 1981-12-28 1983-08-11 Takeda Chem Ind Ltd セラチオペプチタ−ゼの安定化法
JPS59134730A (ja) 1983-01-20 1984-08-02 Green Cross Corp:The 血液凝固第８因子の加熱処理法
IL74909A (en) 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
NZ226170A (en) 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
DE69010518T2 (de) 1989-01-30 1994-11-03 Corint Ltd Wässerige Desmopressin-CMC enthaltende Arzneizubereitung.
JPH02268681A (ja) * 1989-04-07 1990-11-02 Green Cross Corp:The ウロキナーゼ前駆体の安定化方法及び乾燥製剤
CA2028848A1 (en) * 1989-04-11 1990-10-12 Tapan Audhya Lyophilized peptide formulations
HU220234B (hu) 1989-10-16 2001-11-28 Amgen Inc. Eljárás stem sejtek működését befolyásoló faktorok előállitására
SG43009A1 (en) 1989-10-16 1997-10-17 Amgen Inc Stem cell factor
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
WO1992000376A1 (en) 1990-06-25 1992-01-09 Immunex Corporation Mast cell growth factor
EP0618807B1 (de) * 1991-12-20 2002-11-13 Novo Nordisk A/S Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
CA2124690C (en) * 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer

Also Published As

Publication number Publication date
AU696860B2 (en) 1998-09-17
CA2182970C (en) 2000-11-28
WO1995017206A1 (en) 1995-06-29
NZ278252A (en) 1998-04-27
HK1008815A1 (en) 1999-05-21
DE69414723D1 (de) 1998-12-24
IL112088A (en) 2001-04-30
ZA9410189B (en) 1995-08-25
ES2123951T3 (es) 1999-01-16
CN1142771A (zh) 1997-02-12
ATE173402T1 (de) 1998-12-15
AU1442295A (en) 1995-07-10
US6288030B1 (en) 2001-09-11
DK0732935T3 (da) 1999-08-02
IL112088A0 (en) 1995-03-15
US5965522A (en) 1999-10-12
US6020469A (en) 2000-02-01
EP0732935B1 (de) 1998-11-18
CN1105575C (zh) 2003-04-16
CA2182970A1 (en) 1995-06-29
US20020013258A1 (en) 2002-01-31
EP0732935A1 (de) 1996-09-25

Similar Documents

Publication Publication Date Title
ATE173402T1 (de) Lyophilisierte stammzellenfaktor formulierungen
FI952119A0 (fi) Stabiili pakastekuivattu koostumus, joka sisältää proteiinia ja testipakkaus
DK0758248T3 (da) Formuleringer til faktor IX
DE3778287D1 (de) Peptidische zusammensetzung.
GR3006172T3 (de)
DK289285A (da) Thymopentin analoge
AU5327386A (en) Peptide derivatives, analogous to pepstatin, which inhibit renin and acid proteases.
ES2107033T3 (es) Peptidos bpc, su preparacion y su utilizacion.
DK0495918T3 (da) Aminosyre-beta-lyaseenzyminhibitorer som deodoranter
FI955130A0 (fi) L-aminohappo-oksidaasi
ES2181763T3 (es) Formulaciones a base de fenbendazol.
ATE41773T1 (de) 4,5-dihydro-4-oxo-2((2-transphenylcyclopropyl)amino>-3-furancarbonsaeuren und derivate davon.
DE69521315D1 (de) Hirudin enthaltende pharmazeutische zusammensetzungen
DE3152363T1 (de)
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge
AU639751B2 (en) Temporary minimal protection synthesis of lh-rh analogs
IT8423664A0 (it) Realizzate in applicazione al detto metodo per la produzione metodo. industriale di calzature, in particolare ciabatte, di notevole leggerezza ed utilizzabili sia da casa che all'aperto, e calzature
NO853069L (no) 2,5-pyrolidindion-derivater.
IT8420913A0 (it) Leggerezza ed utilizzabili sia da metodo per la produzione casa che all'aperto, e calzature industriale di calzature, in realizzate in applicazione al detto particolare ciabatte, di notevole metodo.
ATE74764T1 (de) Peptidische zusammensetzung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BIOVITRUM AB (PUBL), STOCKHOLM, SE